Soy isoflavone complex
Natural health product licensed in Canada
- Licence holder
- Canadian Phytopharmaceuticals Corporation
- NPN or DIN-HM
- 80055784
- Status
- Active licence
- Licence date
- 20 November 2014
- Revision date
- 15 December 2014
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Stéarate de magnésium, Gélatine, Eau purifiée, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes ménopausées et en postménopause | Not specified | minimum: 6 Capsule ; maximum: 7 Capsule | 1 day |
Uses authorised in Canada
Helps to attenuate/reduce bone mineral density (BMD) loss in post-menopausal women when used in conjunction with adequate amounts of calcium and vitamin D. May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Ensure you are up-to-date on mammograms and gynecological evaluations prior to use. Consult a physician if symptoms worsen. Consult a physician prior to use if you are taking blood thinners or hormone replacement therapy (HRT) including hyroid hormone replacement therapy. Consult a physician prior to use if you have a history of hormonal or gynecological disease, including ovarian cancer, endometriosis and/or dark uterine fibroids, or if you have a liver disorder or develop liver-related symptoms (e.g. abdominal pain, jaundice, dark urine). Discontinue use and consult a physician if you experience breast pain, discomfort and/or tenderness, or if you experience a recurrence of menstruation and/or uterine spotting.
- Contre-indications
Do not use if you have or previously had breast cancer and/or breast tumours or if you have a predisposition to breast cancer, as indicated by an abnormal mammorgram and/or biopsy, or a family member with breast cancer.
Source
Official Health Canada record, licence 80055784
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2014. Photograph the packaging to check whether it has changed. Photograph the packaging